Skip to main content

Table 7 Multivariable Cox proportional hazards regression on hospitalization in the subsequent period

From: Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis

 

Hospitalizationa

 

Hazard Ratio (95 % CI)

P-value*

Race

 White vs. non-white

0.50 (0.32–0.79)

0.003*

Lung-function decline group

 Marginal decline vs. stable

2.50 (1.06–5.91)

0.033*

 Significant decline vs. stable

3.37 (1.62–7.00)

<0.001*

BMI

 25–30 vs. <25

0.59 (0.34–1.03)

0.061

 ≥30 vs. <25

0.95 (0.51–1.74)

0.861

Comorbidities

 Cardiac disorder vs. no cardiac disorder

1.87 (1.06–3.32)

0.032*

 Pulmonary hypertension vs. no pulmonary hypertension

2.09 (1.15–3.83)

0.017*

 Emphysema vs. no emphysema

1.44 (0.62–3.36)

0.399

 Gastroesophageal reflux disease vs. no gastroesophageal reflux disease

1.08 (0.67–1.73)

0.746

Smoking status

 History of smoking vs. no history of smoking

1.02 (0.61–1.70)

0.935

Suspected AEx in the concurrent period

 Yes vs. no

1.86 (1.06–3.26)

0.030*

Use of prednisone and azathioprine in the concurrent period

 Both vs. neither

1.24 (0.59–2.62)

0.575

 Prednisone only vs. neither

1.25 (0.72–2.16)

0.428

 Azathioprine only vs. neither

0.74 (0.09–6.38)

0.780

Symptoms at initial IPF diagnosis

 Dyspnea vs. no dyspnea

1.43 (0.43–4.80)

0.562

 Weight loss vs. no weight loss

1.45 (0.77–2.76)

0.250

Physician's main practice setting

 Academic vs. non-academic

0.89 (0.51–1.55)

0.680

GAP index (per unit increase)b

1.23 (1.04–1.46)

0.018*

  1. aMultivariable Cox proportional hazard regression was used to estimate the hazard ratio, 95 % confidence interval and p-value, accounting for physician clustering using generalized estimating equations
  2. bThe hazard ratio for the GAP index was estimated for every one point increase in GAP index
  3. *P-values less than 0.05 are indicated with an asterisk (*)